Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension

Background High Density Lipoprotein Cholesterol (HDL-C) has various anti-inflammatory, anti-atherogenic, anti-oxidant and anti-coagulant properties that improve vascular function. The utility of HDL-C as a biomarker of severity and predictor of survival was described in patients with pulmonary arterial hypertension (PAH). No prior study has assessed the utility of HDL-C in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Objectives We aim to measure HDL-C levels in CTEPH patients and compare it to those in PAH patients and controls and determine HDL-C associations with markers of disease severity, hemodynamics and mortality in CTEPH. Methods We retrospectively included patients with CTEPH, identified from the Cleveland Clinic Pulmonary Hypertension Registry. All patients had right heart catheterization (RHC) and imaging studies consistent with CTEPH. We collected demographics, co-morbidities, baseline laboratory data including plasma HDL-C, six-minute walk test (6MWT), echocardiography and RHC. HDL-C levels were compared to a cohort of patients with cardiovascular risk factors and a previously published PAH cohort. Results HDL-C levels were available for 90 patients with CTEPH (age: 57.4±13.9 years; female 40%), 69 patients with PAH (age: 46.7±12.8 years; female 90%) and 254 control subjects (age: 56.7±13 years; female 48%). HDL-C levels in CTEPH patients were lower compared to controls and higher compared to PAH patients (median, IQR: CTEPH: 44, 34–57 mg/dl; PAH: 35.3, 29–39 mg/dl; Control: 49, 40–60 mg/dl; p < 0.01 for both pairwise comparisons). In CTEPH, higher HDL-C was associated with decreased prevalence of right ventricular dilation on echocardiography (p = 0.02). 57 patients with CTEPH underwent pulmonary thromboendarterectomy, higher HDL-C was associated with a larger decrement in postoperative pulmonary vascular resistance (PVR) (r = 0.37, p = 0.049). HDL-C was not associated with mortality or other markers of disease severity. Conclusions HDL-C levels in CTEPH patients were lower compared to control subjects, but higher compared to PAH patients. Higher HDL-C in CTEPH was associated with less right ventricular dilation and greater decrement in postoperative PVR. These data suggest that HDL-C may be a useful marker of small vessel disease in CTEPH.

[1]  G. Kopeć,et al.  HDL Cholesterol as a Marker of Disease Severity and Prognosis in Patients with Pulmonary Arterial Hypertension , 2019, International journal of molecular sciences.

[2]  Yunxia Zhang,et al.  Circulating biomarkers in chronic thromboembolic pulmonary hypertension , 2019, Pulmonary circulation.

[3]  A. Makino,et al.  Pulmonary vascular dysfunction in metabolic syndrome , 2018, The Journal of physiology.

[4]  H. Ghofrani,et al.  Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension , 2017, European Respiratory Review.

[5]  R. Dweik,et al.  Abnormal Glucose Metabolism and High‐Energy Expenditure in Idiopathic Pulmonary Arterial Hypertension , 2017, Annals of the American Thoracic Society.

[6]  P. Dorfmüller,et al.  The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension. , 2016, Annals of the American Thoracic Society.

[7]  S. Kushwaha,et al.  Usefulness of High-Density Lipoprotein Cholesterol to Predict Survival in Pulmonary Arterial Hypertension. , 2016, The American journal of cardiology.

[8]  W. Seeger,et al.  The Clinical Significance of HbA1c in Operable Chronic Thromboembolic Pulmonary Hypertension , 2016, PloS one.

[9]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[10]  Simon Gibbs,et al.  [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.

[11]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[12]  M. Madani,et al.  Chronic thromboembolic pulmonary hypertension. , 2014, The Lancet. Respiratory medicine.

[13]  E. Michelakis,et al.  The Metabolic Theory of Pulmonary Arterial Hypertension , 2014, Circulation research.

[14]  M. Humbert,et al.  Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. , 2014, Circulation research.

[15]  W. Seeger,et al.  Algorithm of Pulmonary Arterial Hypertension , 2022 .

[16]  W. Klepetko,et al.  Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy , 2013, Thorax.

[17]  M. Humbert,et al.  Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[18]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[19]  W. Seeger,et al.  HbA1c in pulmonary arterial hypertension: a marker of prognostic relevance? , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  Z. Jing,et al.  Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. , 2012, The American journal of cardiology.

[21]  M. Madani,et al.  Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2,700 patients. , 2012, The Annals of thoracic surgery.

[22]  Y. E. Chen,et al.  Human apolipoprotein A-I induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through ATP-binding cassette transporter A1. , 2011, American journal of physiology. Cell physiology.

[23]  W. Klepetko,et al.  Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. , 2011, The Journal of thoracic and cardiovascular surgery.

[24]  T. Rice,et al.  Unrecognized glucose intolerance is common in pulmonary arterial hypertension. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[25]  R. Dweik,et al.  Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.

[26]  H. Vliegen,et al.  Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism , 2010, Haematologica.

[27]  G. Hansmann,et al.  Insulin resistance in pulmonary arterial hypertension , 2008, European Respiratory Journal.

[28]  P. Corris,et al.  Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.

[29]  M. Olschewski,et al.  Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension , 2008, European Respiratory Journal.

[30]  J. Pepke-Żaba,et al.  Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. , 2007, Respiratory medicine.

[31]  Ahmad Y. Sheikh,et al.  Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferator–Activated Receptor-&ggr; Activation , 2007 .

[32]  Paolo Prandoni,et al.  Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. , 2004, The New England journal of medicine.

[33]  Shirin Rahmani,et al.  Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment , 2003, Circulation.

[34]  G. Franceschini,et al.  Endothelial Protection by High-Density Lipoproteins: From Bench to Bedside , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[35]  P. Shaul Regulation of endothelial nitric oxide synthase: location, location, location. , 2002, Annual review of physiology.

[36]  Richard G. W. Anderson,et al.  High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase , 2001, Nature Medicine.

[37]  A. von Eckardstein,et al.  High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[38]  J. Viikari,et al.  Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. , 1999, Atherosclerosis.

[39]  José A Fernández,et al.  High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. , 1999, The Journal of clinical investigation.

[40]  H. Sinzinger,et al.  Hyperalphalipoproteinemia and prostaglandin I2 stability. , 1997, Thrombosis research.

[41]  A Giaid,et al.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.

[42]  R. Epand,et al.  HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[43]  K. Moser,et al.  Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. , 1993, Chest.

[44]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[45]  E. Mohler,et al.  Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. , 1991, The American journal of cardiology.

[46]  T. Aoyama,et al.  Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. , 1990, Circulation.

[47]  C Kawai,et al.  Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. , 1988, The Journal of clinical investigation.